AllDocs -> cancers

©2005 MC5690 Advocacy for brain cancer : The SPORE works closely with the North American Brain Tumor Consortium (NABTC), which provides support through their website and telephone for brain cancer patients and caregivers. NABTC and its components are also active in increasing funding support for research in brain cancer . Administration: The SPORE is organized through an Administrative Core and guided by an Executive Committee, with input from External and Internal Advisory Committees. Executive Committee Brian Patrick O’Neill, M.D. (Overall Principal Investigator) Robert B. Jenkins, M.D., Ph.D. (Overall Co-Principal Investigator) Jann N. Sarkaria, M.D. Evanthia Galanis, M.D, DSc Joseph P. Loftus, Ph.D. Ping Yang, M.D., Ph.D. Caterina Giannini, MD., Ph.D. Karla Ballman, Ph.D. Jan C. Buckner, M.D. C. David ...

DEPARTMENT OF VETERANS AFFAIRS Veterans Health Administration Washington DC 20420 IL 10-2005-020 In Reply Refer To: 131 September 15, 2005 UNDER SECRETARY FOR HEALTH’S INFORMATION LETTER NEW STUDY REPORTING INCREASED RISK OF BRAIN CANCER DEATHS AMONG 1991 GULF WAR VETERANS POSSIBLY EXPOSED TO SARIN CHEMICAL WARFARE AGENT AT KHAMISIYAH, IRAQ 1. Purpose. This Under Secretary for Health’s Information Letter provides information to clinicians who: a. Examine and provide care to veterans who may have been exposed to low levels of chemical warfare nerve agents including sarin during March 1991 weapons demolitions at Khamisiyah, Iraq, and b. May have concerns about how such exposures may have affected the veteran’s health. 2. Background a. A recent scientific study (“Mortality in US Army Gulf War Veterans Exposed to 1991 Khamisiyah Chemical ...

YM BIOSCIENCES PARTNER, ONCOSCIENCE AG, REPORTS UPDATE OF PEDIATRIC BRAIN CANCER DATA - Nimotuzumab (Theraloc;TheraCIM h-R3) Phase II results awarded best poster prize at the 37 th congress of the International Society of Paediatric Oncology - MISSISSAUGA, Canada – September 27, 2005 – YM BioSciences Inc. (AMEX:YMI, TSX:YM, AIM:YMBA), the cancer product development company, today announced that updated data from a Phase II monotherapy trial of nimotuzumab in children with resistant or relapsed high-grade gliomas ( brain cancers) were reported in a poster presented on September 23 rd , 2005 at the 37 th Congress of The International Society of Paediatric Oncology in Vancouver, Canada. Nimotuzumab produced cytotoxic efficacy and evidence of survival benefit in children with heavily pretreated relapsed high grade gliomas, especially those with ...

BRAIN CANCER 12 THE ONCOLOGY REPORT / Fall 2005 Brain Cancer For more meeting reports, visit www.OncologyReport.com © 2005 Elsevier Inc. All rights reserved. Brain Cancer Commentary by Henry S. Friedman, MD INDEX Enzastaurin (LY317615), 13 IL13-PE38QQR (IL13PE), 12 Methotrexate, 15 Microdialysis, 15 NCCN guidelines, 13 NCCTG GBM trials, 14 Progression-free survival, 14 Temozolomide (Temador), 13 Thalidomide (Thalomid), 14 Whole brain radiation therapy, 14 AMERICAN SOCIETY OF CLINICAL ONCOLOGY Peritumoral administration best way to deliver IL13PE Adequate catheter positioning important determinant of drug distribution and survival outcome Peritumoral administration appears to optimize the delivery of IL13PE in patients undergoing tumor resection. ...

Incidence and Mortality Rate Trends The incidence and mortality rates for cancers that originate in the brain and central nervous system (CNS) have remained relatively unchanged in the last decade. Both incidence and mortality rates are substantially higher for Whites than for other racial/ethnic groups. Regardless of racial/ethnic group, men have higher incidence and mortality rates than women. Brain and other CNS cancers are the second leading cause of cancer -related death in children and make up 21 percent of all childhood cancers. In comparison to adults, the absolute number of brain and CNS cancer deaths in children is smaller and survival rates are higher. Source for incidence and mortality data: Surveillance, Epidemiology, and End Results (SEER) Program and the National Center for Health Statistics. Additional statistics and charts available ...

1 Brain Cancer Microarray Data Gene Co-expression Network Analysis R Tutorial Steve Horvath, Bin Zhang, Jun Dong, Andy Yip, Ai Li Correspondence: shorvath@mednet.ucla.edu , http://www.ph.ucla.edu/biostat/people/horvath.htm This R tutorial describes how to carry out a gene co-expression network analysis with the R software. We show how to construct unweighted networks using hard thresholding and how to construct weighted networks using soft thresholding. To cite this tutorial or the statistical methods please use 1. Zhang B, Horvath S (2005) A General Framework for Weighted Gene Co-Expression Network Analysis. Statistical Applications in Genetics and Molecular Biology. In Press. Technical Report and software code at: www.genetics.ucla.edu/labs/horvath/CoexpressionNetwork . For the generalized topological overlap matrix as applied to unweighted ...

CombinatoRx and ABC 2 Initiate Brain Cancer Collaboration Partnership Speeds Search for Brain Cancer Cure BOSTON, MA and BURLINGAME, CA - Sept. 27, 2004 - CombinatoRx, Incorporated, a privately held pharmaceutical com- pany, and Accelerate Brain Cancer Cure (ABC 2 ), a non-profit foundation dedicated to accelerating therapies leading to a cure for brain cancer , today announced that they have initiated a research collaboration aimed at identifying novel multi-target drugs for the treatment of brain cancer . The sponsored research will leverage the CombinatoRx proprietary combination high throughput screening (cHTS) platform in an effort to discover novel drug combinations that hit multiple targets relevant to glioblastoma multiforme (GBM), a deadly form of brain cancer . The cHTS platform allows CombinatoRx to uncover synergistic activities of drug combinations ...

Abstract. Although conventional chemotherapies are used to treat patients with malignancies, damage to normal cells is problematic. Blood-forming bone marrow cells are the most adversely affected. It is therefore necessary to find alternative agents that can kill cancer cells but have minimal effects on normal cells. We investigated the brain cancer cell-killing activity of a homeopathic medicine, Ruta, isolated from a plant, Ruta graveolens . We treated human brain cancer and HL-60 leukemia cells, normal B-lymphoid cells, and murine melanoma cells in vitro with different concentrations of Ruta in combination with Ca 3 (PO 4 ) 2 . Fifteen patients diagnosed with intracranial tumors were treated with Ruta 6 and Ca 3 (PO 4 ) 2 . Of these 15 patients, 6 of the 7 glioma patients showed complete ...

Morphing into Cancer : The Role of Developmental Signaling Pathways in Brain Tumor Formation Marie P. Fogarty, Jessica D. Kessler, Robert J. Wechsler-Reya Department of Pharmacology and Cancer Biology, Duke University Medical Center, Durham, North Carolina 27710 Received 10 January 2005; accepted 11 January 2005 ABSTRACT: Morphogens play a critical role in most aspects of development, including expansion and patterning of the central nervous system. Activating germline mutations in components of the Hedgehog and Wnt pathways have provided evidence for the important roles morphogens play in the genesis of brain tumors such as cerebellar medulloblastoma. In addition, aberrant expression of transforming growth factor-b (TGF-b) superfamily members has been demonstrated to contribute to progression of malignant gliomas. This review summarizes our current knowledge ...

Navajo Nation Littlefield Kingman Wil iams Ajo Flagstaff-Rural Wel ton/ Dateland Hopi Nation Payson Maricopa Co. W St. Johns Quartzsite/Salome Graham Co. S Page/Fredonia Dolan Springs Hualapai Holbrook Tohono O'Odham Nation Arivaca Wil cox/Bowie San Carlos Apache Chino Val ey /Ash Fork Florence Benson Wickenburg Yavapai Co. S/Bagdad Tombstone/Elfrida White Mountain Apache Eloy San Manuel Maricopa Co. N Bisbee Yavapai Co. NE Tubac/Patagonia D u n c a n / M o r e n c i R o u n d V a l e y Cordes Junction G lo b e / H a y d e n Superior /Kearny Heber-Overgaard /Snowflake Maricopa ...

Arizona Brain Cancer , Age-Adjusted Incidence Rate, 1995 to 2000, by CHAA CHAA CHAA ID Case Count Six-Year Total Population Age- Adjusted Rate Lower Confidence Bound Upper Confidence Bound Littlefield 1 0 31,032 Kaibab Paiute 2 0 1,726 Dolan Springs 3 2 29,059 2.45 -0.95 5.84 Hualapai 4 0 7,181 Kingman 5 19 253,211 6.30 3.38 9.21 Bullhead City 6 15 236,395 4.75 2.18 7.31 Fort Mohave 7 4 40,155 5.70 0.01 11.40 Lake Havasu City 8 21 240,762 7.07 3.77 10.38 Page/Fredonia 9 2 52,075 3.48 -1.41 8.37 Navajo Nation 10 8 571,929 1.56 0.40 2.71 Hopi ...

For Immediate Release Date: June 30, 2005 Contact: Kay Verble Phone: 904-273-8755 904-626-8046 Fax: 904-273-8745 Local Foundation One of Eight Philanthropic Organizations United To Defeat Brain Cancer Brain Tumor Funders’ Collaborative to “Fast Track” Lab Research Towards Viable Medical Treatments June 30, 2005/ Today, in an unprecedented collaboration among private funding organizations throughout North America, eight organizations, including The Sontag Foundation, announced they are jointly requesting proposals for new ways to develop effective treatments for children and adults diagnosed with brain tumors. Joining The Sontag Foundation as eight founding members of the Brain Tumor Funders’ Collaborative (BTFC) are: the American Brain Tumor Association, Brain Tumour Foundation of Canada, Brain Tumor Society, Children’s Brain Tumor Foundation, ...

Eight Philanthropic Organizations Unite to Defeat Brain Cancer Brain Tumor Funders’ Collaborative to “Fast Track” Lab Research Towards Viable Medical Treatments June 30, 2005 / Today, in an unprecedented collaboration among private funding organizations throughout North America, eight organizations announced they are jointly requesting proposals for new ways to develop effective treatments for children and adults diagnosed with brain tumors. The eight founding members of the Brain Tumor Funders’ Collaborative (BTFC) are: the American Brain Tumor Association, Brain Tumour Foundation of Canada, Brain Tumor Society, Children’s Brain Tumor Foundation, the Goldhirsh Foundation, the James S. McDonnell Foundation, the National Brain Tumor Foundation and the Sontag Foundation. BTFC’s goal is bridging the “translational gap” that prevents promising laboratory findings from yielding ...

ORIGINAL CONTRIBUTION Handheld Cellular Telephone Use and Risk of Brain Cancer Joshua E. Muscat, MPH Mark G. Malkin, MD, FRCPC Seth Thompson, PhD Roy E. Shore, PhD Steven D. Stellman, PhD Don McRee, PhD Alfred I. Neugut, MD, PhD Ernst L. Wynder, MD† S INCE THE INTRODUCTION OF CEL - lular telephone service in the UnitedStatesin1984, 1 thenum- ber of subscribers has in- creased substantially every year. By the end of 1999, there were more than 86 million cellular telephone users. 2 Cel- lular telephones, which include hand- held or mobile telephones, car tele- phones,andportableorbagtelephones, operate on radiofrequency (RF) sig- nals in the 800- to 900-MHz range. Concernshavebeenraisedaboutpos- sible adverse health effects due to expo- sure to these signals. In particular, alle- ...

BENIGN BRAIN TUMOR CANCER REGISTRIES AMENDMENT ACT: Improving the Quality of Brain Tumor Data Background Each year, approximately 35,000 individuals in the United States are diagnosed with primary brain tumors. About half of those tumors are “benign.” However, it is difficult to differentiate between benign and malignant tumors on the basis of their microscopic appearance; some benign tumors have a propensity to become malignant over time; and some benign brain tumors recur repeatedly. Benign brain tumors may be no more responsive to treatment than malignant tumors, and both benign and malignant brain tumors present daunting treatment challenges because of their location. Improvements in our understanding of brain tumors and advances in the treatment of brain tumors depend on the collection of accurate data about brain tumors. Both the Brain Tumor Working Group of the National ...

The machinists union contacted the Connecticut Department of Public Health to assist them in evaluating a concern of their mem- bers and families regarding a cluster of brain cancer cases at the North Haven facility. Those who were concerned had developed a list of persons they suspected had brain cancer who had worked at the facility. Since the number of cases was consistent with a need for follow-up, the DPH conducted a formal investigation during the summer and fall of 2000. There were several purposes in conducting the study: • Confirm the diagnoses of these cases medically. If tumors were found, see if they were malignant brain tumors. • Determine if there were any other cases. • Determine whether there were more cases of brain cancer oc- curring in P&W employees than would be expected based on comparison with the overall population in Connecticut. ...

Division of Environmental Epidemiology & Occupational Health 410 Capitol Avenue MS#11EOH PO Box 340308 Hartford, CT 06134-0308 • Many of the cases initially suggested by the union were ruled out because they were not malignant brain tumors. Some were brain tumors that were either benign (non-cancerous) or were a metastasis from an- other type of tumor. The brain is a common site to which a malignant tumor (a metastasis), which be- gins in another part in the body, can spread. Only malignant brain tumors were considered part of the investigation. Benign brain tumors have different risk factors. • There were four cases of primary, malignant (cancerous) brain tumors confirmed among white male employees at the P&W North Haven facility during the period 1991-1999. Three of these were the same type. The four individuals with primary brain tumors had worked ...

CANCER of the BRAIN and OTHER NERVOUS SYSTEM Pennsylvania Department of Health - Pennsylvania Cancer Incidence and Mortality 2002 - Page 164 While some cases show an autosomal dominant pattern, no genetic factor has been found to influence the overall incidence of primary nervous system tumors. Etiological factors are obscure. Risk Factors FIGURE 19 Average Annual Age-Adjusted Incidence and Mortality Rates* by Sex and Race, Pennsylvania Residents, 1998-2002 None proven to be effective or currently being evaluated. Early Detection During 2002, there were 929 invasive cases of brain and other central nervous system cancers reported to the Pennsylvania Cancer Registry – the highest number recorded between 1993 and 2002. The average annual (1998-2002) age-adjusted incidence rates were higher for whites than blacks and the rate for white males was over ...

Cancer Type Males Females Total Bladder 103 100 102 Brain 103 95 99 Breast 71 110 110 Cervix NC 118 118 Colon 115 110 112 Esophagus 90 115 97 Hodgkin's Disease 139 88 116 Kidney 100 115 106 Larynx 115 59 103 Leukemia 121 82 105 Liver 93 112 99 Lung 99 133 112 Melanoma 138 133 135 Mouth 94 117 101 Myeloma 78 104 90 NHL 87 104 95 Ovary NC 100 100 Pancreas 111 113 112 Prostate 130 NC 130 Stomach 94 90 93 Testis 122 NC 122 Thyroid 94 113 107 Uterus NC NC 94 Other 105 99 102 ...

Massachusetts Department Of Public Health Bureau of Environmental Health Assessment, Community Assessment Program Assessment of Brain and Central Nervous System Cancer Incidence in Needham, MA 1987-1998 December, 2002 Page 2 Assessment of Brain and Central Nervous System Cancer Incidence in Needham, MA 1987-1998 T ABLE OF C ONTENTS I. INTRODUCTION .1 II. OBJECTIVES1 III. METHODS FOR ANALYZING CANCER INCIDENCE 3 A. Case Identification.3 B. Calculation of Standardized Incidence Ratios (SIRs)..3 C. Calculation of 95% Confidence Interval 5 D. Evaluation of Risk Factor Information 6 E. Determination of Geographic Distribution6 IV. METHODS FOR ASSESSING ENVIRONMENTAL INFORMATION..7 ...

TimePeriod Obs Exp SIR Obs Exp SIR Obs Exp SIR 1982 - 1988 33 30.1 110 75 -- 154 13 13.5 96 51 -- 164 20 16.6 121 1989 - 1995 33 29.6 111 77 -- 156 15 14.1 107 60 -- 176 18 15.6 116 1996 - 2001 26 20.0 130 85 -- 190 12 10.4 116 60 -- 202 14 9.6 145 Note: SIRs are calculated based on the exact number of expected cases. Expected number of cases presented are rounded to the nearest tenth. SIRs and 95% CI are not calculated when observed number of cases < 5. Obs = Observed number of cases 95% CI = 95% Confidence Interval Exp = Expected number of cases NC = Not calculated SIR = Standardized Incidence Ratio * = Statistical significance Data Source: Massachusetts ...

1672 Main St. Ste. E #264 • Ramona, CA 92065 • Tel: 760.789.8928 • Fax: 760.789.8929 • Toll Free: 800.475.1955 • www.proteinbiotechnologies.com HUMAN BRAIN CANCER TISSUE MICROARRAY Catalog Number: TMA-016 Each core from each tissue represents one specimen selected and pathologically confirmed. Normal matched or unmatched brain tissue is provided for comparison to the cancer tissue. Cases : 76 Cores : 80 Diameter : 1.5 mm Thickness: 5 µm Standard IHC: Anti-Glial Fibrillary Acid Protein antibody confirmed Layout : 8 x 10 1 2 3 4 5 6 7 8 9 10 A 1 2 3 4 5 6 7 8 9 10 B 11 12 13 14 15 16 17 18 19 20 C 21 22 23 24 25 26 ...

March 11, 2005 Volume 2 No. 19 USE YOUR HEAD How students are using tattoos to solicit blood donations Page 4 THE BIG PICTURE How ‘Mr. Small Science’ links science and society Page 5 INSIDE THE CCIT Take a quiz on your knowledge of CCIT activities Pages 6 & 7 D I S C O V E R Y E N E R G Y C R E A T I V I T Y C O M M U N I T Y HOPE FOR BRAIN CANCER VICTIMS HOPE FOR BRAIN CANCER VICTIMS Page 3 Dr. Greg Cairncross and patient Don McHenry examine MRIs of McHenry’s brain . / Photo by Ken Bendiktsen Page 2 2 MARCH 11, 2005 on CAMPUS Volume 2, Number 18 OnCampus is published 31 times a year by the office of the Vice President (External Relations.) Editorial ...

Cancer Incidence by Remoteness Category in Queensland Cancer of the Brain Meninges and other central nervous system 0 3 6 9 12 15 0 3 6 9 12 15 Male Female Rate per 100,000 population Rate per 100,000 population Avg No. Avg No. per Year per Year Incidence of Cancer of the Brain Meninges and other central nervous system, by ARIA+ Category and Sex, Queensland, Five Year Average, 1998 to 2002 9.1 77 6.2 58 Major City ARIAplus Category 8.1 39 6.4 32 Inner Regional 7.7 24 6.2 19 Outer Regional 5.8 2 2.4 1 Remote 6.1 1 2.6 1 Very remote Note: Rates are age standardised to the ...

Cancer Mortality by Remoteness Category in Queensland Cancer of the Brain Meninges and other central nervous system 0 3 6 9 12 15 0 3 6 9 12 15 Male Female Rate per 100,000 population Rate per 100,000 population Avg No. Avg No. per Year per Year Mortality of Cancer of the Brain Meninges and other central nervous system, by ARIA+ Category and Sex, Queensland, Five Year Average, 1998 to 2002 7.1 58 4.8 46 Major City ARIAplus Category 6.2 30 4.8 24 Inner Regional 6.1 18 4.2 12 Outer Regional 3.1 1 3.9 1 Remote 2.4 1 1.3 0 Very remote Note: Rates are age standardised to the ...

Cancer Incidence by Geographical Reporting Area in Queensland Cancer of the Brain Meninges and other central nervous system 0 3 6 9 12 15 0 3 6 9 12 15 Male Female Rate per 100,000 population Rate per 100,000 population Avg No. Avg No. per Year per Year Incidence of Cancer of the Brain Meninges and other central nervous system, by Geographical Reporting Area and Sex, Queensland, Five Year Average, 1998 to 2002 9.8 8 4.4 4 Bayside Geographical Area 10.1 24 5.9 16 Brisbane North 8.9 16 5.9 12 Brisbane South 7.2 9 5.9 7 Darling Downs/Sth West 8.2 8 4.7 5 Far North 5.5 ...

Cancer Mortality by Socioeconomic Status in Queensland Cancer of the Brain Meninges and other central nervous system 0 3 6 9 12 15 0 3 6 9 12 15 Male Female Rate per 100,000 population Rate per 100,000 population Avg No. Avg No. per Year per Year Mortality of Cancer of the Brain Meninges and other central nervous system, by SEIFA category and Sex, Queensland, Five Year Average, 1998 to 2002 7.3 16 4.5 11 High SES SEIFA Quintile 6.8 21 4.2 15 Mod. high SES 6.4 21 5.8 20 Moderate SES 5.8 26 4.1 19 Mod. Low SES 7.0 24 5.2 19 Low SES Note: Rates are age standardised ...